Fig. 3

ROC curves of CB2 receptor and MOR gene and lL-17, OPN, MCP-1 and IFN-γ levels between patients

The ROC curves of CB2 (Cannabinoid receptor 2) and MOR (μ-opioid receptor) gene levels and lL-17 (Interleukin-17), MCP-1 (Monocyte Chemoattractant Protein-1), OPN (Osteopontin) and IFN-γ (Interferon-γ) levels between different groups are shown. Assessing values were calculated using receiver operating characteristic (ROC) curve analysis, and the area under the curve (AUC) and optimal cut-off values were determined based on the Youden index. Notably, the patients were divided into two categories: severe and non-severe; Severe patient had acute clinical manifestations of the disease and high virus concentration in the nasopharyngeal specimen (CT value of gene expression below 20) and were hospitalized; while, non-severe patients had mild respiratory symptoms and low virus concentration in the nasopharyngeal specimen (CT value of gene expression greater than 30) and were not assessed for hospitalization. (A): Indicates CB2 receptor expression level in female group with severe and non-severe SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2); (B): Indicates CB2 receptor expression level in male group with severe and non-severe SARS-CoV-2, (C): Indicates MOR expression level in female group with severe and non-severe SARS-CoV-2, (D): Indicates MOR expression level in male group with severe and non-severe SARS-CoV-2.(E): Indicates lL-17 level in male group with severe and non-severe SARS-CoV-2; (F): Indicates lL-17 level in female group with severe and non-severe SARS-CoV-2, (G): Indicates MCP-1 level in male group with severe and non-severe SARS-CoV-2, (H): Indicates MCP-1 level in female group with severe and non-severe SARS-CoV-2; (I): Indicates OPN level in male group with severe and non-severe SARS-CoV-2; (J): Indicates OPN level in female group with severe and non-severe SARS-CoV-2, (K): Indicates IFN-γ level in male group with severe and non-severe SARS-CoV-2; (L): Indicates IFN-γ level in female group with severe and non-severe infection. Statistical details are presented in Table 2